CARD14 Antibody

中文名稱：

CARD14兔多克隆抗體
貨號：

CSB-PA883622LA01HU
規(guī)格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human breast cancer using CSB-PA883622LA01HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human placenta tissue using CSB-PA883622LA01HU at dilution of 1:100

Immunofluorescence staining of Hela cells with CSB-PA883622LA01HU at 1:100, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) CARD14 Polyclonal antibody
Uniprot No.：

Q9BXL6
基因名：

CARD14
別名：

Bcl10 interacting MAGUK protein 2 antibody; Bimp 2 antibody; Bimp2 antibody; CAR14_HUMAN antibody; CARD 14 antibody; CARD containing MAGUK 2 protein antibody; CARD containing MAGUK protein 2 antibody; Card maguk protein 2 antibody; CARD-containing MAGUK protein 2 antibody; CARD14 antibody; Carma 2 antibody; Carma2 antibody; Caspase recruitment domain containing protein 14 antibody; Caspase recruitment domain family member 14 antibody; Caspase recruitment domain protein 14 antibody; Caspase recruitment domain-containing protein 14 antibody; PRP antibody; PSORS2 antibody; PSS1 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Caspase recruitment domain-containing protein 14 protein (249-523AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁面中的產(chǎn)品，CARD14 Antibody (CSB-PA883622LA01HU)，的標(biāo)記方式是Non-conjugated。對于CARD14 Antibody，我們還提供其他標(biāo)記。見下表：

標(biāo)記方式	貨號	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA883622LB01HU	CARD14 Antibody, HRP conjugated	ELISA
FITC	CSB-PA883622LC01HU	CARD14 Antibody, FITC conjugated
Biotin	CSB-PA883622LD01HU	CARD14 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Acts as a scaffolding protein that can activate the inflammatory transcription factor NF-kappa-B and p38/JNK MAP kinase signaling pathways. Forms a signaling complex with BCL10 and MALT1, and activates MALT1 proteolytic activity and inflammatory gene expression. MALT1 is indispensable for CARD14-induced activation of NF-kappa-B and p38/JNK MAP kinases. May play a role in signaling mediated by TRAF2, TRAF3 and TRAF6 and protects cells against apoptosis.; Not able to activate the inflammatory transcription factor NF-kappa-B and may function as a dominant negative regulator.
基因功能參考文獻(xiàn)：
1. Results identified RNF7 to interact with CARMA2 regulating its NF-kappaB-activating capacity. Mechanistically, RNF7 influences CARMA2 signaling by regulating the ubiquitination state of MALT1 and the NF-kappaB-regulatory molecule NEMO. Interestingly, CARMA2short (CARMA2sh) mutants associated with psoriasis susceptibility escape the negative control exerted by RNF7. PMID: 29194363
2. The serine/threonine kinase ULK2 binds to and phosphorylates CARMA2sh. PMID: 28230860
3. MALT1 deficiency or pharmacological inhibition of MALT1 catalytic activity inhibits pathogenic mutant CARD14-induced cytokine and chemokine expression in human primary keratinocytes. PMID: 27113748
4. CARD14/MALT1-mediated signaling in keratinocytes has a role in psoriasis [review] PMID: 27939769
5. The results indicate that the common CARD14 p.Arg820Trp variant might have a significant effect on the response to anti-TNF therapies among patients with psoriasis. In addition, rare CARD14 missense variants could also predispose to a better response. PMID: 26854129
6. Our findings, combined with the published literature, suggest that Pityriasis Rubra Pilaris Type V, both familial and sporadic, can be caused by CARD14 mutations. PMID: 27760266
7. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-kappaB activation PMID: 27071417
8. genetic evidence suggests association of the CARD14 single nucleotide polymorphism rs11652075 and other rare mutations in this gene with psoriasis. To assess whether combined data support the relationship between CARD14 rs11652075 and susceptibility to this disease, we conducted a meta-analysis. Our results demonstrate a significant association between the CARD14 rs11652075 polymorphism and psoriasis. PMID: 27706581
9. SNP c.C2458T may have significant effects on heritability of psoriasis vulgaris in our Chinese population. The CC genotype was more common in familial cases than in sporadic cases. PMID: 26249641
10. The authors observations provide further insights into the genetics of psoriasis and functional information on novel CARD14 mutational variants seen in cases from Tunisia and other populations. PMID: 26358359
11. Genetic interactions of SNPs in CARD14, SENP1 and VEGFA might represent a functional mechanism in the pathogenesis of high altitude polycythemia. PMID: 26852650
12. We found five rare mutations and four of them are annotated or reported. Only the variant (c.1291C>G) has not been reported and annotated, but the variant was also found in controls. None of the new definite variants were pathogenic PMID: 26982778
13. analysis of 105 individuals with generalized pustular psoriasis (GPP) identified a low-frequency variant (p.Asp176His) that causes constitutive CARD14 oligomerization PMID: 26203641
14. CARD14 protein missense mutation found in patients diagnosed with psoriasis. PMID: 25989471
15. no definite causative genetic mutation in CARD14 as identified in familial pityriasis rubra pilaris after screening 8 non-familial patients of type I, type III and type IV pityriasis rubra pilaris PMID: 24577624
16. The study identified the DEP domain-containing protein DEPDC7 as cellular binding partner of CARMA2 and CARMA3 proteins. PMID: 25541973
17. CARD14 mutation maybe responsible for activation of NF-kB signaling pathway in patients with pityriasis rubra pilaris. PMID: 25734815
18. Transfection of dermal ECs with psoriasis-associated CARD14 mutations resulted in increased expression of several chemokines, including CXCL10, IL-8, and CCL2. PMID: 25369198
19. Variant analysis of CARD14 in a Chinese Han population with psoriasis vulgaris and generalized pustular psoriasis shows that CARD14 may play a role in the pathogenesis of generalized pustular psoriasis. PMID: 24999592
20. Owing to the relatively small number of cases analysed in this study, we cannot rule out the possibility that CARD14 mutations may be an exceptional cause of sporadic pityriasis rubra pilaris, as previously found in sporadic psoriasis PMID: 24359224
21. Mutations and variants are causal or disease susceptibility factors of psoriasis vulgaris, generalized pustular psoriasis, or pityriasis rubra pilaris. [review] PMID: 24656634
22. Chromosome 17q25 harbors a susceptibility locus for psoriasis. Non-parametric linkage analysis revealed a linkage peak lying close to a novel cluster of genes from the immunoglobulin (Ig) superfamily. PMID: 12483297
23. Our results confirmed the published linkage with the PSORS1 locus, as well as the PSORS2 locus, which has not been previously shown in the Chinese population. PMID: 12709815
24. These results fail to support rs734232 as a psoriasis susceptibility factor in German psoriasis patients. PMID: 15654961
25. PSORS2 alleles are not susceptibility factors in arthritis psoriatic patients of Italian origin PMID: 16733365
26. Results show genetic heterogeneity of psoriasis in the Tunisian population, provide confirmatory evidence for a novel psoriasis locus at chromosome 2p12 and reveal a psoriasis family with a mutation at PSORS2. PMID: 23013406
27. Pityriasis rubra pilaris autosomal dominant family is an allelic disease to certain genetic forms of familial psoriasis. PMID: 23328365
28. CARD14 c.526G>C (p.Asp176His) may have a role in generalized pustular psoriasis with psoriasis vulgaris in Japanese patients PMID: 24476623
29. the association between SNP rs11652075 at the CARD14 gene and psoriasis PMID: 23905699
30. we identified three different heterozygous mutations in CARD14 causing familial pityriasis rubra pilaris. PMID: 22703878
31. Here, rare, highly penetrant mutations in CARD14 have been shown to cause psoriasis. PMID: 22521418
32. A range of NF-kB responses in the skin are mediated by CARD14 and that a subset of rare CARD14 variants leads to psoriasis and psoriatic arthritis. PMID: 22521419
33. Results demonstrate that multiple transcripts encoding several CARMA2 isoforms exist in vivo and regulate NF-kappaB activation and apoptosis. PMID: 21302310
顯示更多

收起更多
相關(guān)疾病：

Psoriasis 2 (PSORS2); Pityriasis rubra pilaris (PRP)
亞細(xì)胞定位：

[Isoform 1]: Cytoplasm.; [Isoform 2]: Cytoplasm.; [Isoform 3]: Cytoplasm.
組織特異性：

Isoform 1 is detected in placenta and epidermal keratinocytes. Isoform 2 is detected in leukocytes and fetal brain.
數(shù)據(jù)庫鏈接：

HGNC: 16446

OMIM: 173200

KEGG: hsa:79092

STRING: 9606.ENSP00000344549

UniGene: Hs.675480

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human